On Tuesday, Ocwen Financial Corp (NYSE:OCN)’s shares declined -5.19% to $8.77, as Ocwen Financial Corporation, stated a preliminary net loss of $(546.0) million, or $(4.18) per share, for the year ended December 31, 2014 contrast to net revenue of $310.4 million, or $2.13 per share, for the year ended December 31, 2013. Ocwen generated preliminary proceed of $2.1 billion, up 4% contrast to $2.0 billion in the preceding year. Preliminary revenue from operations was $76.1 million for the year ended December 31, 2014.
Preliminary pre-tax loss for 2014 was $(443.2) million, contrast to $352.5 million pre-tax revenue in 2013. Preliminary pre-tax revenue on a normalized basis for 2014 was $284.9 million, contrast to the $550.4 million normalized pre-tax revenue in 2013. During 2014, Ocwen incurred a total of $728.1 million in preliminary normalized expenses. Normalization items in 2014 comprise $420.2 million of goodwill impairment, $186.1 million of legal and settlement expenses primarily related to the settlement with the New York Department of Financial Services, $72.3 million for MSR-related fair value changes and $49.5 million of transition and other items. The preliminary normalized results for 2014 were influenceed by and comprise $127.3 million of servicer expenses and uncollectible advances together with $39.4 million in regulatory monitoring costs. In addition, our preliminary net loss results comprise a charge to record an about $77 mil
Ocwen Financial Corporation, through its auxiliaries, is engaged in the servicing and origination of mortgage loans in the United States and internationally. The corporation’s Servicing segment provides residential and commercial mortgage loan servicing, special servicing, and asset administration services to owners of mortgage loans and foreclosed real estate.
iKang Healthcare Group Inc (ADR) (NASDAQ:KANG)’s shares dropped -4.90% to $17.29, during the last trading session on Tuesday, as iKang Healthcare Group, launched its personalized medical examination mobile app on March 27, 2015.
One of the key features of iKang’s preventative healthcare services is to fully inform individuals about the findings from the latest discoveries and research, and the latest clinical guidelines from around the world, especially from the US and China. By empowering individuals with a greater understanding of their own health and lifestyles before medical examinations, the iKang Medical Exam APP will make more personalized recommendations for individuals to take the necessary diagnostic tests and make the experience more effective. In its essence, the iKang Medical Exam APP is founded on balancing the risks and rewards of preventative medical examinations and providing individuals with well-informed choices.
iKang Healthcare Group, Inc., together with its auxiliaries, provides preventive healthcare solutions in the People’s Republic of China. The corporation offers a range of medical examinations, which comprise internal, gynecology, ophthalmology, ENT, dental, lab tests, electrocardiogram, ultrasound, and X-ray examination items
At the end of Tuesday’s trade, Pinnacle Entertainment, Inc (NYSE:PNK)‘s shares dipped -5.98% to $34.11, as Pinnacle Entertainment, declared that it will release its 2015 first quarter financial results on Thursday, April 23, 2015 preceding to the market opening, followed by a conference call on the same day at 10:00 a.m. ET (7:00 a.m. PT).
Pinnacle Entertainment, Inc. owns, develops, and operates casinos and related hospitality and entertainment facilities in the United States. Its Midwest segment operates Ameristar Council Bluffs, Ameristar East Chicago, Ameristar Kansas City, Ameristar St. Charles, Belterra, Belterra Park, and River City properties.
Idera Pharmaceuticals Inc (NASDAQ:IDRA), ended its Tuesday’s trading session with -4.66% loss, and closed at $3.68, as Idera Pharmaceuticals, declared that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of diffuse large B-cell lymphoma (DLBCL).
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical corporation, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
